Association Between Sarcopenic Obesity and Metabolic Syndrome in Adults: A Systematic Review and Meta-Analysis

Khadra, Dima; Itani, Leila; Chebaro, Yomna; Obeid, May; Jaber, Miryam; Ghanem, Reham A.; Ayton, Agnes; Kreidieh, Dima; Masri, Dana El; Kimura, Akira; Tannir, Hana; Ghoch, Marwan El

doi:10.2174/1573403x16666200214104122

Cited by 17 publications

(7 citation statements)

References 40 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The pooled OR showed that sarcopenic obesity was associated with a 38 % increase in odds of type 2 diabetes compared with those without sarcopenic obesity Khadra et al (76) Meta-analysis n 11 308 Twelve studies Men and women…”

Section: Various Measurementsmentioning

confidence: 99%

“…Sarcopenic obesity was significantly associated with a 38 % increase in risk of type 2 diabetes compared with those without sarcopenic obesity (OR 1•38, 95 % CI 1•27, 1•50), but results should be interpreted with caution as the majority of studies were cross-sectional. A meta-analysis has also been carried out to synthesise the results of studies assessing the associations between sarcopenia obesity and the metabolic syndrome, including twelve studies with a total of 11 308 overweight or obese adults (76) . Pooled analysis showed that sarcopenic obese participants did not have a significantly increased risk of the metabolic syndrome (risk ratio 1•08, 95 % CI 0•99, 1•17) compared with those with obesity only.…”

Section: Various Measurementsmentioning

confidence: 99%

See 1 more Smart Citation

Sarcopenic obesity in ageing: cardiovascular outcomes and mortality

Atkins¹,

Wannamathee

2020

Br J Nutr

117

View full text Add to dashboard Cite

Obesity is a major public health issue with prevalence increasing worldwide. Obesity is a well-established risk factor for CVD and mortality in adult populations. However, the impact of being overweight or obese in the elderly on CVD and mortality is controversial. Some studies even suggest that overweight and obesity, measured by BMI, are apparently associated with a decreased mortality risk (known as the obesity paradox). Ageing is associated with an increase in visceral fat and a progressive loss of muscle mass. Fat mass is positively associated and lean mass is negatively associated with risk of mortality. Therefore, in older adults BMI is not a good indicator of obesity. Sarcopenia has been defined as the degenerative loss of muscle mass, quality and strength with age and is of major concern in ageing populations. Sarcopenia has previously been associated with increased risks of metabolic impairment, cardiovascular risk factors, physical disability and mortality. It is possible for sarcopenia to co-exist with obesity, and sarcopenic obesity is a new class of obesity in older adults who have high adiposity levels together with low muscle mass, quality or strength. Therefore, sarcopenia with obesity may act together to increase their effect on metabolic disorders, CVD and mortality. This review will discuss the available evidence for the health implications of sarcopenic obesity on CVD and mortality in older adults.

show abstract

Section: Various Measurementsmentioning

confidence: 99%

Section: Various Measurementsmentioning

confidence: 99%

Sarcopenic obesity in ageing: cardiovascular outcomes and mortality

Atkins¹,

Wannamathee

2020

Br J Nutr

117

View full text Add to dashboard Cite

show abstract

“…В систематическом обзоре и метаанализе, выполненном Khadra D. и соавт. (2019), включавшем 11 308 пациентов обоих полов с избыточной массой тела или ожирением, было показано, что СД2 и СО имеют сильную патогенетическую взаимосвязь [21].…”

Section: этиология и патогенез соunclassified

Sarcopenic obesity — a current problem of modern geriatrics

Kurmaev

Bulgakova

Treneva

2023

Rossiiskii zhurnal geriatricheskoi meditsiny

View full text Add to dashboard Cite

Sarcopenic obesity (SO) is a complex metabolic state of the body, attributable to a synergistic combination, mutual reinforcement and aggravation of the pathological mechanisms of sarcopenia and obesity. SO is associated with a decrease in the quality of life, dependence on outside help, an increased risk of disability and premature death. Currently, the urgency of the SO problem is increasing due to the global demographic aging of the population, the high incidence of obesity, type 2 diabetes mellitus (DM2), geriatric syndromes of sarcopenia and frailty in the developed countries of the modern world. It is of interest to review current literature data on the prevalence, etiology, pathogenesis, as well as the principles of diagnosis, prevention and treatment of sarcopenic obesity.

show abstract

“…The changes in body composition (affecting mainly protein), decreasing turnover of structural proteins [ 677 ], and thus, reducing their reposition and functionality, do not necessarily affect body lipid stores. Thus, sarcopenia can often develop while maintaining obesity (e.g., sarcopenic obesity) [ 678 , 679 ]. The obese can become sarcopenic and frail while maintaining their main energy (TAG) stores full, with a largely unused mass of fat which constitutes an additional burden [ 680 ].…”

Section: The Use Of Androgens For the Treatment Of Functional Disordersmentioning

confidence: 99%

The Roles of Androgens in Humans: Biology, Metabolic Regulation and Health

Alemany

2022

IJMS

View full text Add to dashboard Cite

Androgens are an important and diverse group of steroid hormone molecular species. They play varied functional roles, such as the control of metabolic energy fate and partition, the maintenance of skeletal and body protein and integrity and the development of brain capabilities and behavioral setup (including those factors defining maleness). In addition, androgens are the precursors of estrogens, with which they share an extensive control of the reproductive mechanisms (in both sexes). In this review, the types of androgens, their functions and signaling are tabulated and described, including some less-known functions. The close interrelationship between corticosteroids and androgens is also analyzed, centered in the adrenal cortex, together with the main feedback control systems of the hypothalamic–hypophysis–gonads axis, and its modulation by the metabolic environment, sex, age and health. Testosterone (T) is singled out because of its high synthesis rate and turnover, but also because age-related hypogonadism is a key signal for the biologically planned early obsolescence of men, and the delayed onset of a faster rate of functional losses in women after menopause. The close collaboration of T with estradiol (E2) active in the maintenance of body metabolic systems is also presented Their parallel insufficiency has been directly related to the ravages of senescence and the metabolic syndrome constellation of disorders. The clinical use of T to correct hypoandrogenism helps maintain the functionality of core metabolism, limiting excess fat deposition, sarcopenia and cognoscitive frailty (part of these effects are due to the E2 generated from T). The effectiveness of using lipophilic T esters for T replacement treatments is analyzed in depth, and the main problems derived from their application are discussed.

show abstract

Association Between Sarcopenic Obesity and Metabolic Syndrome in Adults: A Systematic Review and Meta-Analysis

Cited by 17 publications

References 40 publications

Sarcopenic obesity in ageing: cardiovascular outcomes and mortality

Sarcopenic obesity in ageing: cardiovascular outcomes and mortality

Sarcopenic obesity — a current problem of modern geriatrics

The Roles of Androgens in Humans: Biology, Metabolic Regulation and Health

Contact Info

Product

Resources

About